Condition: Hodgkin Lymphoma in Remission · Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna
Study design: It is a monocentric and exploratory study, experimental on human tissues in vitro which involves the analysis of peripheral blood in patients with Hodgkin's lymphomas with the following characteristics: * in complete remission for at least two years after first-line therapy with stage IIb, III or IV at onset (Ann Arbor classification). * newly diagnosed (stage IIb, III or IV, Ann Arbor Classification).
This description comes directly from the study's public registry record.
Pier Luigi Zinzani, MD · +390512144042 · pierluigi.zinzani@unibo.it
Cinzia Pellegrini, MD · +390512103680 · cinzia.pellegrini@aosp.bo.it
Always discuss trial participation with your own doctor first.
| IRCCS Azienda Ospedaliero - Universitaria di Bologna | Bologna, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06761274